Heymach J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.06.
Stereotactische radiotherapie plus immuuntherapie verbetert event-vrije overleving
nov 2023 | Longoncologie, Radiotherapie